Inmed granted 180-day extension to achieve nasdaq minimum bid compliance

Vancouver, british columbia--(newsfile corp. - march 20, 2024) - inmed pharmaceuticals inc. (nasdaq: inm) ("inmed" or the "company"), a leader in the manufacturing, development and commercialization of rare cannabinoids and proprietary cannabinoid analogs, today announced that it has received a notification letter from the listing qualifications department of nasdaq stock market llc ("nasdaq") that the company has been granted an additional 180-day compliance period, or until september 16, 2024 (the "extended compliance period"), to regain compliance with nasdaq's minimum bid price requirement for the continued listing on the nasdaq capital market, as set forth in nasdaq listing rule 5550(a)(2) (the "minimum bid price rule"). nasdaq's determination is based on the company meeting the continued listing requirement for market value of publicly held shares and all other applicable requirements for initial listing on the nasdaq capital market, with the exception of the bid price requirement, and the company's written notice of its intention to consider all available options to regain compliance during the extended compliance period, including, if necessary, effecting a reverse stock split.
INM Ratings Summary
INM Quant Ranking